In the present study, we sought to determine the therapeutic efficiency of PTC-209, a novel and selective inhibitor of Bmi1, against HNSCC using both in vitro cell culture and in vivo xenograft animal model. This evidence concerns the gene BMI1 and head and neck squamous cell carcinoma.